Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 1997

View Archived Issues

Synthetic retinoids with anticoagulant effects

SDZ-MRL-953 prevents sepsis in cancer patients

Preclinical profile of Ono-1101 published

SciClone issued European patent for use of thymosin alpha 1 for hepatitis C

Matrix discontinues U.S. development of AccuSite

Biomira reports phase II results for cancer vaccine

Preclinical studies show broad antiseizure properties of ganaxolone

Oncologic Drugs Advisory Committee meets this week

LG Chemical licenses thrombin inhibitor to Warner-Lambert

NC-1800 now in phase II development

Chugai accelerates R&D outside Japan

Pharmacological characterization of BIBU-52

Kirin's TPO enters phase II in several Asian countries

Kyowa Hakko antiparkinsonian enters phase II trials

Amphetamines may provide long-term benefit in patients with ADHD

MIT licenses drug discovery technology to Dyax

Benefits of magnesium sulfate investigated in patients with unstable angina

Cytel and Searle to collaborate on cancer therapies

Myocardial and cerebral vasodilating effects of BMS-180448 in animals

Molecumetics and Teijin begin oral thrombin inhibitor collaboration

Potent GH secretagogues synthesized at Merck & Co.

Gene Logic and Japan Tobacco enter genomic alliance

Novel antibacterial agents from R.W. Johnson

Novartis evaluates SDZ-267-489 and analogues for increasing HDL cholesterol

Cardiovascular effects of SB-209509 and sumatriptan compared in dogs

Hormone therapy vs. simvastatin for hypercholesterolemia in postmenopausal women

Novel neuroprotective agent developed at Takeda

Mitsubishi describes synthesis and activity of MKC-242

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.